Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. W.W.H. Roeloffzen

Publicaties

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy

Conditioning With High Dose Total Body Irradiation And Post Transplantation Cyclophosphamide in Early Relapsed Multiple Myeloma Patients Receiving Allogeneic Stem Cell Transplantation

Lees meer